Is INCY a Buy? What to Consider in 2026

Last updated July 2026

Short answer

The bull case for Incyte Corporation (INCY) rests on Jakafi franchise still growing near-term: Jakafi remains the profit engine, posting roughly $758 million in Q1 2026 net sales on about 6% prescription demand growth across myelofibrosis, polycythemia vera, and GVHD. Revenue (TTM) is ~$4.8B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. Whether INCY is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology. Its flagship product is Jakafi (ruxolitinib), an oral JAK inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease, which still generates the largest share of company revenue (roughly $758 million in Q1 2026, up about 7%). Beyond Jakafi, Incyte sells the topical cream Opzelura (ruxolitinib) for atopic dermatitis and vitiligo, plus a widening hematology and oncology lineup including Monjuvi/Minjuvi, Niktimvo, and Zynyz, and it funds a broad clinical pipeline of oncology and immunology candidates. The investment picture is defined by one number and one date: Jakafi's US loss of exclusivity in December 2028. Incyte is profitable and cash-rich (about $4.0 billion in cash and marketable securities as of Q1 2026) and has been growing fast, with Q1 2026 total revenue near $1.27 billion, up about 21% year over year, and non-Jakafi sales rising sharply. Management's stated goal is to build $3 billion to $4 billion of non-Jakafi revenue by the time the patent cliff hits. The bull case is that Opzelura, newer launches, and pipeline readouts (such as the vitiligo candidate povorcitinib and combination programs) offset the decline; the bear case is heavy dependence on a single aging drug, clinical trial risk, and a setback such as the FDA's rejection of an extended-release Jakafi formulation.

What's the case for buying INCY?

1. Jakafi franchise still growing near-term

Jakafi remains the profit engine, posting roughly $758 million in Q1 2026 net sales on about 6% prescription demand growth across myelofibrosis, polycythemia vera, and GVHD. That cash flow funds the entire R&D and commercial buildout. The near-term question is how long Incyte can keep growing the franchise before generic ruxolitinib arrives.

2. Non-Jakafi revenue diversification

Opzelura grew about 20% to roughly $143 million in Q1 2026, and the hematology/oncology portfolio (Niktimvo, Monjuvi/Minjuvi, Zynyz) more than doubled to around $204 million. Management targets $3 billion to $4 billion of non-Jakafi revenue by the 2028 cliff. The pace of these ramps is the central bull-case variable.

3. Pipeline and combination strategy

Incyte is advancing candidates such as the vitiligo drug povorcitinib and combination programs pairing Jakafi with assets like the ALK2 inhibitor zilurgisertib and a BET inhibitor. Positive late-stage readouts could open new indications and extend the ruxolitinib platform. Pipeline outcomes are the swing factor for revenue beyond 2028.

4. Strong balance sheet and profitability

The company ended Q1 2026 with about $4.0 billion in cash and marketable securities and reaffirmed full-year net sales guidance of roughly $4.77 billion to $4.94 billion. That financial cushion gives Incyte capacity to fund internal R&D or pursue business development to backfill the Jakafi cliff. Capital allocation decisions will shape the diversification outcome.

What are the risks to INCY?

The dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. Pipeline and launch execution carry real uncertainty, as shown by the FDA's rejection of the once-daily extended-release Jakafi formulation, and clinical trials can fail at any stage. Competition is intensifying from larger peers with deeper resources in both oncology (Bristol Myers Squibb, Novartis, AbbVie) and inflammation/dermatology (AbbVie's Rinvoq, Eli Lilly's Olumiant, Pfizer, Regeneron). Morningstar has downgraded Incyte's economic moat toward none, citing the looming patent loss. If non-Jakafi revenue does not scale to the $3 billion to $4 billion goal in time, the company could face a revenue gap late this decade.

How is INCY valued? (as of JULY 2026)

Price

$116.71

Market cap

$23.32B

P/E (TTM)

16.48

Forward P/E

13.83

Price / book

4.15

Beta

0.76

52-week range

$67.17 to $118.97

Snapshot for INCY as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$4.8B
Q1 2026 revenue: ~$1.27B (up ~21% YoY)
Jakafi Q1 2026 net sales: ~$758M
Cash & marketable securities: ~$4.0B
Market cap: ~$23-24B
Forward P/E: ~12x (trailing ~14-16x)

Incyte trades at a modest multiple for a profitable biopharma, with a forward P/E around 12x reflecting strong recent earnings growth but investor caution about the 2028 Jakafi cliff. The trailing P/E collapsed from triple digits in early 2025 to the mid-teens through 2026 as earnings normalized. Figures are approximate as of mid-2026 and move with reported results and the share price.

How do you decide if INCY is a buy?

Rather than asking whether INCY is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold INCY indirectly through an index or sector ETF before adding more.

For the full picture, see the INCY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about INCY against your real portfolio and see your actual exposure before deciding.

The bottom line on INCY

The bottom line: Incyte Corporation's story right now is Jakafi franchise still growing near-term, with revenue (ttm) at ~$4.8B. If you believe that narrative continues, the call is about sizing INCY sensibly and checking overlap with what you own; if you doubt it (the risk: the dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

Build a basket around INCY with Walnut

Use Incyte Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is INCY a good stock to buy right now?

The case for Incyte Corporation right now is Jakafi franchise still growing near-term, with revenue (ttm) at ~$4.8B. If you believe that thesis holds, INCY is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does Incyte Corporation do?

Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology.

What are the main risks of INCY?

What does Incyte do?

Incyte is a biopharmaceutical company focused on oncology, hematology, and dermatology. Its lead drug is Jakafi (ruxolitinib), a JAK inhibitor for myelofibrosis, polycythemia vera, and graft-versus-host disease, and it also sells the Opzelura skin cream and a growing portfolio of hematology and oncology medicines.

Why does Jakafi's 2028 patent matter so much?

Jakafi generates the largest share of Incyte's revenue, so its US loss of exclusivity in December 2028 is the single biggest overhang on the stock. Once generic ruxolitinib can enter, Jakafi sales are expected to decline, which is why Incyte is racing to build non-Jakafi revenue before then.

How fast is Incyte growing?

In Q1 2026, Incyte reported total revenue of about $1.27 billion, up roughly 21% year over year, with non-Jakafi products like Opzelura and its newer hematology/oncology drugs growing especially fast. Management reaffirmed full-year net sales guidance of roughly $4.77 billion to $4.94 billion.

Is Incyte profitable?

Yes. Incyte is profitable and cash-generative, reporting Q1 2026 EPS around $1.81 and ending the quarter with about $4.0 billion in cash and marketable securities. That balance sheet gives it capacity to fund R&D and potential business development to offset the Jakafi cliff.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell INCY; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.